×

Lumenis Unites with Women Suffering from Endometriosis and Their Supporters at the 3rd Annual Worldwide EndoMarch to Raise Awareness of This Overlooked Disease

YOKNEAM, Israel, March 18, 2016 (GLOBE NEWSWIRE) -- Lumenis Ltd., the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications, announced today the company’s support in the 3rd Annual Worldwide EndoMarch, an international event bringing together women and their supporters to raise awareness of endometriosis. This year’s EndoMarch will be celebrated on Saturday, March 19.

Since 2014, the EndoMarch movement has encouraged thousands of women from around the world to unite in raising awareness about endometriosis, a disorder in which the endometrium, or the tissue that lines a woman’s uterus, grows outside of the uterus onto other organs. Its main symptoms are associated with pelvic pain and infertility. Infertility occurs in up to half of women affected by this condition. While there is no cure for endometriosis, Lumenis unique UltraPulse® and AcuPulse™ technologies are perceived as superior surgical tools amongst leading surgeons specializing in endometriosis. UltraPulse® and AcuPulse™ are able to operate precisely around delicate anatomy with minimal thermal damage while preserving healthy tissue, resulting in reduced healing time and lower recurrence rates of the disease. As a consequence, fertility preservation rates may also be improved following the delicate CO2 laser treatment.

“While endometriosis is a treatable condition, it continues to be one of the most ignored public health crises of our time. Because the majority of women overlook their endometriosis symptoms and attribute them to other causes, women often face diagnostic delays of 10 years or more. These diagnostic delays may result in increased severity of the condition and fertility challenges,” said Camran Nezhat, MD, FACOG, FACS, founder of the Worldwide EndoMarch. “As a global initiative, EndoMarch calls on all women, those fighting endometriosis and their supporters, to join together to raise awareness around this serious disease. Beyond disease awareness, it is especially important for women to be informed about endometriosis treatment options and Lumenis CO2 laser technology, one of the advanced options for better patient care.”

The Worldwide EndoMarch will take place in dozens of cities in the U.S., including San Francisco, New York, Washington, D.C., and spans internationally to India, Germany, Nigeria, Brazil, Australia and more. The largest chapter event will be held in San Francisco, where a group of Lumenis employees will participate and support the movement.

“Endometriosis impacts one in 10 women, which is approximately 200 million women worldwide,” said Tzipi Ozer-Armon, CEO of Lumenis. “The recently launched UltraPulse® DUO system demonstrates once again our commitment to developing the best technology that improves gynecological-related health conditions. In addition to innovative technological solutions, we are very involved in patient education efforts. We believe that EndoMarch is an ideal platform to empower and educate women about endometriosis, its symptoms, risks and the treatment options available, and we are pleased to be part of this annual international event.”

To learn more about Lumenis CO2 Laser technology for the treatment of endometriosis please visit: http://www.lumenis.com/Solutions/Surgical/Procedures/Gynecology.

About Lumenis
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. For more information visit: www.lumenis.com


For further information: Glenn Silver Lazar Partners Ltd. (646) 871-8495

Source:Lumenis Ltd.